OABI

OmniAb, Inc. (OABI) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. OmniAb, Inc. is a biotechnology company that licenses discovery research technology to the pharmaceutical and biotech industry. Its platform utilizes "Biological Intelligence" in engineered transgenic animals to identify optimal antibodies. As of June 30, 2024, the company had 83 active partners and 333 active programs, including 28 antibodies in clinical development and 3 approved products.

Key Financial Metrics

Note: Cash and short-term investments combined total $57.2 million as of June 30, 2024 ($20.8M cash + $36.4M short-term investments).

Material Changes vs. Prior Period

• Revenue Volatility: While Q2 2024 revenue increased 10% year-over-year, the six-month revenue declined 52% to $11.4 million. This was primarily driven by a $13.1 million decrease in license and milestone revenue, largely due to a $10 million milestone recognized in the prior year related to the first commercial sale of TECVAYLI in the EU.
• Service Revenue Growth: Service revenue increased 70% in Q2 and 8% for the six months, attributed to changes in ion channel research programs and revenue acceleration from program discontinuations.
• Operating Expenses: Total operating expenses decreased 9% in Q2 and 3% for the six months. General and administrative expenses declined due to lower share-based compensation and the absence of non-recurring separation costs from the prior year.
• Contingent Liability Adjustment: The company recorded a $2.6 million reduction in contingent liabilities (recognized as other operating income), primarily attributed to changes in ion channel programs.
• Intangible Asset Impairment: A $1.2 million impairment was recorded for finite-lived intangible assets related to legacy acquisitions, increasing amortization expense.

Outlook, Risks, and Management Commentary

• Liquidity: Management believes existing cash, cash equivalents, and short-term investments ($57.2 million) will support operations for at least the next 12 months. The company has an "at-the-market" (ATM) sales agreement with Jefferies LLC for up to $100 million, though no shares have been sold as of June 30, 2024.
• Warrants: The company has approximately 19 million warrants outstanding (Public, Private, Forward Purchase, and Backstop) with an exercise price of $11.50. These are currently "out of the money," and no cash proceeds are expected from exercise until the stock price rises above this threshold.
• Risks: Revenue is heavily dependent on partner milestones and future royalties, which are subject to significant uncertainty regarding clinical success and regulatory approval. The company continues to incur losses as it invests in R&D and platform expansion.
• Unusual Items: The $2.6 million gain from the reduction of contingent liabilities and the $1.2 million intangible asset impairment are non-recurring items impacting the current period's operating results.

Investor Verification Checklist

• Revenue Sustainability: Verify the pipeline of upcoming milestones, given the significant drop in license/milestone revenue compared to the prior year.
• Cash Burn Rate: Monitor the $29.2 million cash used in operating activities over the last six months against the $57.2 million cash balance to assess runway.
• Contingent Liabilities: Review the fair value assumptions for the remaining $1.5 million in contingent liabilities, as changes here can significantly impact net income.
• Warrant Dilution: Assess the potential dilution from ~19 million warrants if the stock price recovers above the $11.50 exercise price.
• Partner Progress: Track the status of the 28 clinical programs and 3 approved products, as these are the primary drivers for future royalty revenue.